Simcere charts new course for early stage drug discovery with VC spin-off
SHANGHAI – Simcere Pharmaceutical Group made headlines in December when it announced plans to go private and delist from the NYSE. As the first Chinese biopharmaceutical company to go public in the U.S. the longtime generics maker – and growing innovative drug developer – is used to taking on pioneering projects, and looks to be at it again.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST